Coulter's Bexxar Data Sends Shares Up
Californian biotechnology company Coulter Pharmaceutical will presentpositive data on Bexxar, its radiolabeled monoclonal antibody for non-Hodgkin's lymphoma, at the American Society of Hematology meeting in December. Shares in the company were up 24% to $3.63 on the day of the announcement.
Last month, Coulter said that preliminary data from its Phase II trial showed that Bexxar outperformed the unlabeled version of the same monoclonal antibody in patients with low-grade NHL.
At the upcoming conference, Coulter is expected to report that tumors shrank more than 50% in 60% of heavily pretreated advanced-stage NHL patients, and that tumors became undetectable in 27% of those treated, according to Kevin Tang of BT Alex Brown. He reiterated his buy rating on the company, and gave it a 12-month price target of $29 per share.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze